AU6536500A - Method for increasing optic nerve, choroidal and retinal blood flow to facilitate the preservation of sight - Google Patents
Method for increasing optic nerve, choroidal and retinal blood flow to facilitate the preservation of sight Download PDFInfo
- Publication number
- AU6536500A AU6536500A AU65365/00A AU6536500A AU6536500A AU 6536500 A AU6536500 A AU 6536500A AU 65365/00 A AU65365/00 A AU 65365/00A AU 6536500 A AU6536500 A AU 6536500A AU 6536500 A AU6536500 A AU 6536500A
- Authority
- AU
- Australia
- Prior art keywords
- agent
- composition
- cyclic
- patient
- gmp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims description 119
- 230000001965 increasing effect Effects 0.000 title claims description 47
- 230000002207 retinal effect Effects 0.000 title claims description 36
- 230000017531 blood circulation Effects 0.000 title description 50
- 210000001328 optic nerve Anatomy 0.000 title description 13
- 238000004321 preservation Methods 0.000 title description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 85
- 239000000203 mixture Substances 0.000 claims description 78
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 claims description 74
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 71
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 claims description 50
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical group OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 claims description 49
- 230000004386 ocular blood flow Effects 0.000 claims description 43
- 229960002639 sildenafil citrate Drugs 0.000 claims description 41
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 35
- 229960003310 sildenafil Drugs 0.000 claims description 34
- 230000002792 vascular Effects 0.000 claims description 32
- 208000002780 macular degeneration Diseases 0.000 claims description 28
- 150000001875 compounds Chemical class 0.000 claims description 23
- 208000035475 disorder Diseases 0.000 claims description 22
- 208000020911 optic nerve disease Diseases 0.000 claims description 22
- 208000001344 Macular Edema Diseases 0.000 claims description 21
- 206010025415 Macular oedema Diseases 0.000 claims description 20
- 201000010230 macular retinal edema Diseases 0.000 claims description 20
- 230000004382 visual function Effects 0.000 claims description 20
- 238000011282 treatment Methods 0.000 claims description 19
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical group [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 claims description 18
- ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 claims description 18
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 claims description 18
- 208000022873 Ocular disease Diseases 0.000 claims description 17
- 108010078321 Guanylate Cyclase Proteins 0.000 claims description 16
- 102000014469 Guanylate cyclase Human genes 0.000 claims description 16
- 210000003161 choroid Anatomy 0.000 claims description 15
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims description 13
- 238000009825 accumulation Methods 0.000 claims description 13
- 206010061323 Optic neuropathy Diseases 0.000 claims description 12
- 208000027129 choroid disease Diseases 0.000 claims description 12
- 230000003412 degenerative effect Effects 0.000 claims description 12
- -1 denbufyllene Chemical compound 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 12
- 206010029113 Neovascularisation Diseases 0.000 claims description 11
- 208000017442 Retinal disease Diseases 0.000 claims description 11
- MALZYBOXBVXCSN-UHFFFAOYSA-N 11h-pyrido[3,2-a]carbazole Chemical class C1=CC2=NC=CC=C2C2=C1C1=CC=CC=C1N2 MALZYBOXBVXCSN-UHFFFAOYSA-N 0.000 claims description 10
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 claims description 10
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 claims description 10
- 229960002768 dipyridamole Drugs 0.000 claims description 10
- 230000004438 eyesight Effects 0.000 claims description 10
- 229950006884 filaminast Drugs 0.000 claims description 10
- STTRYQAGHGJXJJ-LICLKQGHSA-N filaminast Chemical compound COC1=CC=C(C(\C)=N\OC(N)=O)C=C1OC1CCCC1 STTRYQAGHGJXJJ-LICLKQGHSA-N 0.000 claims description 10
- 229960003711 glyceryl trinitrate Drugs 0.000 claims description 10
- REZGGXNDEMKIQB-UHFFFAOYSA-N zaprinast Chemical compound CCCOC1=CC=CC=C1C1=NC(=O)C2=NNNC2=N1 REZGGXNDEMKIQB-UHFFFAOYSA-N 0.000 claims description 10
- 229950005371 zaprinast Drugs 0.000 claims description 10
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 9
- RRRUXBQSQLKHEL-UHFFFAOYSA-N piclamilast Chemical compound COC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OC1CCCC1 RRRUXBQSQLKHEL-UHFFFAOYSA-N 0.000 claims description 9
- 229950005184 piclamilast Drugs 0.000 claims description 9
- 235000010288 sodium nitrite Nutrition 0.000 claims description 9
- HJMQDJPMQIHLPB-UHFFFAOYSA-N zardaverine Chemical compound C1=C(OC(F)F)C(OC)=CC(C2=NNC(=O)C=C2)=C1 HJMQDJPMQIHLPB-UHFFFAOYSA-N 0.000 claims description 9
- 229950001080 zardaverine Drugs 0.000 claims description 9
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims description 8
- YEESUBCSWGVPCE-UHFFFAOYSA-N azanylidyneoxidanium iron(2+) pentacyanide Chemical compound [Fe++].[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.N#[O+] YEESUBCSWGVPCE-UHFFFAOYSA-N 0.000 claims description 8
- 206010012601 diabetes mellitus Diseases 0.000 claims description 8
- 239000003119 guanylate cyclase activator Substances 0.000 claims description 8
- 230000000302 ischemic effect Effects 0.000 claims description 8
- 229960002460 nitroprusside Drugs 0.000 claims description 8
- 102000008299 Nitric Oxide Synthase Human genes 0.000 claims description 7
- 108010021487 Nitric Oxide Synthase Proteins 0.000 claims description 7
- 150000002429 hydrazines Chemical class 0.000 claims description 7
- 239000002840 nitric oxide donor Substances 0.000 claims description 7
- 150000004005 nitrosamines Chemical class 0.000 claims description 7
- 230000000638 stimulation Effects 0.000 claims description 7
- 239000000725 suspension Substances 0.000 claims description 7
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 6
- 206010025421 Macule Diseases 0.000 claims description 6
- 230000002757 inflammatory effect Effects 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 6
- 208000028867 ischemia Diseases 0.000 claims description 6
- 208000010038 Ischemic Optic Neuropathy Diseases 0.000 claims description 5
- 208000007135 Retinal Neovascularization Diseases 0.000 claims description 5
- 208000004644 retinal vein occlusion Diseases 0.000 claims description 5
- 230000000699 topical effect Effects 0.000 claims description 5
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 claims description 4
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 claims description 4
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 claims description 4
- 206010038910 Retinitis Diseases 0.000 claims description 4
- 201000007058 anterior ischemic optic neuropathy Diseases 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 239000000790 retinal pigment Substances 0.000 claims description 4
- 201000006853 toxic maculopathy Diseases 0.000 claims description 4
- 208000003435 Optic Neuritis Diseases 0.000 claims description 3
- 208000030768 Optic nerve injury Diseases 0.000 claims description 3
- 208000002367 Retinal Perforations Diseases 0.000 claims description 3
- 208000008709 Retinal Telangiectasis Diseases 0.000 claims description 3
- 206010044245 Toxic optic neuropathy Diseases 0.000 claims description 3
- 231100000265 Toxic optic neuropathy Toxicity 0.000 claims description 3
- 230000002489 hematologic effect Effects 0.000 claims description 3
- 208000029233 macular holes Diseases 0.000 claims description 3
- 201000002165 neuroretinitis Diseases 0.000 claims description 3
- 206010003694 Atrophy Diseases 0.000 claims description 2
- 208000034577 Benign intracranial hypertension Diseases 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 208000018127 Idiopathic intracranial hypertension Diseases 0.000 claims description 2
- 206010022557 Intermediate uveitis Diseases 0.000 claims description 2
- 208000009702 Optic Disk Drusen Diseases 0.000 claims description 2
- 201000010183 Papilledema Diseases 0.000 claims description 2
- 206010033708 Papillitis Diseases 0.000 claims description 2
- 206010038848 Retinal detachment Diseases 0.000 claims description 2
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 2
- 230000037444 atrophy Effects 0.000 claims description 2
- 201000002166 optic papillitis Diseases 0.000 claims description 2
- 208000001381 pseudotumor cerebri Diseases 0.000 claims description 2
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims 11
- 229940126514 guanylate cyclase activator Drugs 0.000 claims 7
- 230000003028 elevating effect Effects 0.000 claims 4
- 102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 claims 3
- 108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 claims 3
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 208000037312 Familial drusen Diseases 0.000 claims 1
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 claims 1
- XKLJHFLUAHKGGU-UHFFFAOYSA-N nitrous amide Chemical compound ON=N XKLJHFLUAHKGGU-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 claims 1
- 229930185107 quinolinone Natural products 0.000 claims 1
- 210000001525 retina Anatomy 0.000 description 35
- 238000012360 testing method Methods 0.000 description 33
- 230000000007 visual effect Effects 0.000 description 32
- 230000004087 circulation Effects 0.000 description 28
- 239000003814 drug Substances 0.000 description 19
- 206010064930 age-related macular degeneration Diseases 0.000 description 18
- 229940079593 drug Drugs 0.000 description 18
- 230000004410 intraocular pressure Effects 0.000 description 18
- 230000035945 sensitivity Effects 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 15
- 201000010099 disease Diseases 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 239000010408 film Substances 0.000 description 13
- 230000008569 process Effects 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 239000000047 product Substances 0.000 description 12
- 230000035508 accumulation Effects 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 210000004556 brain Anatomy 0.000 description 11
- 230000002503 metabolic effect Effects 0.000 description 11
- 238000009472 formulation Methods 0.000 description 9
- 239000003981 vehicle Substances 0.000 description 9
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 8
- 229940094720 viagra Drugs 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 239000000835 fiber Substances 0.000 description 7
- 108091008695 photoreceptors Proteins 0.000 description 7
- 230000000541 pulsatile effect Effects 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- 206010034960 Photophobia Diseases 0.000 description 6
- 210000005226 corpus cavernosum Anatomy 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 208000011325 dry age related macular degeneration Diseases 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 208000013469 light sensitivity Diseases 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 239000002699 waste material Substances 0.000 description 6
- 201000004569 Blindness Diseases 0.000 description 5
- 208000003098 Ganglion Cysts Diseases 0.000 description 5
- 208000005400 Synovial Cyst Diseases 0.000 description 5
- 239000008186 active pharmaceutical agent Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 229940088679 drug related substance Drugs 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 210000005036 nerve Anatomy 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000006196 drop Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 239000003380 propellant Substances 0.000 description 4
- 230000002685 pulmonary effect Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 3
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 3
- 101100135868 Dictyostelium discoideum pde3 gene Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- KITLPLLNIZOYIJ-UUOKFMHZSA-N [[(2r,3s,4r,5r)-5-(2-amino-6-oxo-7,8-dihydro-3h-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C1=2NC(N)=NC(=O)C=2NCN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O KITLPLLNIZOYIJ-UUOKFMHZSA-N 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 102000030621 adenylate cyclase Human genes 0.000 description 3
- 108060000200 adenylate cyclase Proteins 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000036770 blood supply Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000000870 hyperventilation Effects 0.000 description 3
- 208000000122 hyperventilation Diseases 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 229940071648 metered dose inhaler Drugs 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 230000004648 relaxation of smooth muscle Effects 0.000 description 3
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- IVYOVCFCGLUEHA-UHFFFAOYSA-N 1,3-dinitrosooxypropan-2-yl nitrite Chemical compound O=NOCC(ON=O)CON=O IVYOVCFCGLUEHA-UHFFFAOYSA-N 0.000 description 2
- OPCMVVKRCLOEDQ-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-(methylamino)pentan-1-one Chemical compound ClC1=CC=C(C=C1)C(C(CCC)NC)=O OPCMVVKRCLOEDQ-UHFFFAOYSA-N 0.000 description 2
- NCGICGYLBXGBGN-UHFFFAOYSA-N 3-morpholin-4-yl-1-oxa-3-azonia-2-azanidacyclopent-3-en-5-imine;hydrochloride Chemical compound Cl.[N-]1OC(=N)C=[N+]1N1CCOCC1 NCGICGYLBXGBGN-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 description 2
- 108091006027 G proteins Proteins 0.000 description 2
- 102000030782 GTP binding Human genes 0.000 description 2
- 108091000058 GTP-Binding Proteins 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 108010044467 Isoenzymes Proteins 0.000 description 2
- 208000035719 Maculopathy Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 2
- 206010039729 Scotoma Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000464 adrenergic agent Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000607 artificial tear Substances 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 210000000467 autonomic pathway Anatomy 0.000 description 2
- 230000010455 autoregulation Effects 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- 230000003376 axonal effect Effects 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 230000001925 catabolic effect Effects 0.000 description 2
- 210000003986 cell retinal photoreceptor Anatomy 0.000 description 2
- 210000003710 cerebral cortex Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 210000004081 cilia Anatomy 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 229940095074 cyclic amp Drugs 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000004340 degenerative myopia Effects 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 2
- 229960000201 isosorbide dinitrate Drugs 0.000 description 2
- 229960003827 isosorbide mononitrate Drugs 0.000 description 2
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000007102 metabolic function Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- 230000001272 neurogenic effect Effects 0.000 description 2
- 208000001749 optic atrophy Diseases 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 229960000502 poloxamer Drugs 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 229960003402 propatylnitrate Drugs 0.000 description 2
- YZZCJYJBCUJISI-UHFFFAOYSA-N propatylnitrate Chemical compound [O-][N+](=O)OCC(CC)(CO[N+]([O-])=O)CO[N+]([O-])=O YZZCJYJBCUJISI-UHFFFAOYSA-N 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000004243 retinal function Effects 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 229940083618 sodium nitroprusside Drugs 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000002504 synaptic vesicle Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 229920001664 tyloxapol Polymers 0.000 description 2
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 2
- 229960004224 tyloxapol Drugs 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 229940124549 vasodilator Drugs 0.000 description 2
- 239000003071 vasodilator agent Substances 0.000 description 2
- 230000004393 visual impairment Effects 0.000 description 2
- 239000003871 white petrolatum Substances 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
- 102000001707 3',5'-Cyclic-AMP Phosphodiesterases Human genes 0.000 description 1
- 108010054479 3',5'-Cyclic-AMP Phosphodiesterases Proteins 0.000 description 1
- 206010053227 AIDS retinopathy Diseases 0.000 description 1
- 241000220479 Acacia Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010054881 Acquired pigmented retinopathy Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- PYQAWXIETKMNIL-UHFFFAOYSA-N CN1CCNC(C1)=S(=O)=O.OC(=O)CC(O)(CC(O)=O)C(O)=O Chemical compound CN1CCNC(C1)=S(=O)=O.OC(=O)CC(O)(CC(O)=O)C(O)=O PYQAWXIETKMNIL-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000029147 Collagen-vascular disease Diseases 0.000 description 1
- 206010058202 Cystoid macular oedema Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 description 1
- 101100135859 Dictyostelium discoideum regA gene Proteins 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010017065 Foster-Kennedy Syndrome Diseases 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 208000007465 Giant cell arteritis Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 206010065534 Macular ischaemia Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010069385 Ocular ischaemic syndrome Diseases 0.000 description 1
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 1
- 101100082606 Plasmodium falciparum (isolate 3D7) PDEbeta gene Proteins 0.000 description 1
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 description 1
- 206010036346 Posterior capsule opacification Diseases 0.000 description 1
- 206010063664 Presumed ocular histoplasmosis syndrome Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 101100135860 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PDE2 gene Proteins 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 208000000859 Sickle cell trait Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 201000002535 age related macular degeneration 10 Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 201000007917 background diabetic retinopathy Diseases 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 210000001775 bruch membrane Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000003222 cGMP degradation Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 201000005667 central retinal vein occlusion Diseases 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 201000010206 cystoid macular edema Diseases 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000005059 dormancy Effects 0.000 description 1
- IAVUPMFITXYVAF-XPUUQOCRSA-N dorzolamide Chemical compound CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 IAVUPMFITXYVAF-XPUUQOCRSA-N 0.000 description 1
- 229960003933 dorzolamide Drugs 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000001856 erectile effect Effects 0.000 description 1
- 210000005225 erectile tissue Anatomy 0.000 description 1
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 210000000873 fovea centralis Anatomy 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 1
- 235000013928 guanylic acid Nutrition 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 208000034737 hemoglobinopathy Diseases 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 230000004402 high myopia Effects 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- 229940125697 hormonal agent Drugs 0.000 description 1
- 238000009474 hot melt extrusion Methods 0.000 description 1
- 239000012943 hotmelt Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229960004657 indocyanine green Drugs 0.000 description 1
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940099367 lanolin alcohols Drugs 0.000 description 1
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 description 1
- 229960001160 latanoprost Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004599 local-density approximation Methods 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 1
- 150000004712 monophosphates Chemical class 0.000 description 1
- 210000000327 mueller cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 230000001883 nitrergic effect Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 201000005799 nutritional optic neuropathy Diseases 0.000 description 1
- 210000003733 optic disk Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 230000005043 peripheral vision Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- PDTFCHSETJBPTR-UHFFFAOYSA-N phenylmercuric nitrate Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 description 1
- 238000007539 photo-oxidation reaction Methods 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 201000010473 primary optic atrophy Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004501 retinal blood flow velocity Effects 0.000 description 1
- 230000004233 retinal vasculature Effects 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000019980 sodium acid phosphate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229940001593 sodium carbonate Drugs 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960001922 sodium perborate Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- YKLJGMBLPUQQOI-UHFFFAOYSA-M sodium;oxidooxy(oxo)borane Chemical compound [Na+].[O-]OB=O YKLJGMBLPUQQOI-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 206010043207 temporal arteritis Diseases 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 208000029517 toxic amblyopia Diseases 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 238000007631 vascular surgery Methods 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Description
WO 01/10406 PCTUSOO/21929 DESCRIPTION METHOD FOR INCREASING OPTIC NERVE, CHOROIDAL AND RETINAL BLOOD FLOW TO FACILITATE THE PRESERVATION OF SIGHT BACKGROUND OF THE INVENTION 5 The present application claims priority to provisional application serial number 60/148,150 filed August 10, 1999. The entire text of the above-referenced disclosure is specifically incorporated by reference herein without disclaimer. 10 1. Field of the Invention The present invention relates generally to the field of ocular medicine. More particularly, it concerns methods for treating ocular disorders and for maintaining ocular health. The present invention relates more specifically to a method for improving visual 15 function and optimizing the health of the optic nerve and retina by increasing blood flow therein through the application of an effective amount of a composition including an agent that increases cyclic-guanosine monophosphate (cyclic-GMP) levels, either directly, or by stimulating cyclic-GMP synthesis, or by inhibiting cyclic-GMP selective phosphodiesterase(s). 20 2. Background Information The vision process in general involves a complex pathway into the brain. To see, light must enter through the cornea and the lens; penetrate the back of the eye through the 25 retina; pass the ganglion cells and bipolar cells; then pass down to the outer plexiform layers through the synaptic vesicle, the inner fiber, the nucleus, the outer fibers, the terminal bars, the cilium; and finally reach the photoreceptors, which can be considered to carry out the instant film processing of the visual light beam. After the light beam has been processed in the photoreceptor disks, it passes back through the cilium, the 30 ellipsoid, myoid, Mueller cells, outer fiber, nucleus, inner fiber, synaptic vesicle, the outer plexiform layer, inner nuclear layer, the bipolar cells, the inner plexiform layer, Q T T 1D Q T TT T U T (DT TT V '1\ WO 01/10406 PCT/USOO/21929 finally reaching the ganglion cells where it is processed into an axon signal. After it reaches the ganglion cells, the signal is transported through the optic nerve fibers to the brain where it is assessed and compounded by the visual brain lobes to form the visual picture. It is believed that the uninterrupted signal carried by the retina, the optic nerve 5 head, and the optic nerve fibers is the most crucial part of the process for creating the visual picture. Adequate blood flow nurtures the tissues along this path and, therefore, assures axonal flow. It is understood that the human eye (and indeed the eye structure of most 10 mammals) has two largely independent circulatory systems, retinal and uveal. Retinal circulation accounts for only about 2% of total eye circulation, but this 2% is critical to the health of the eye's neural connection to the brain, i.e., the 1.2 million axons which make up the nerve trunk known as the optic nerve. The cell bodies containing the genetic material and metabolic machinery for this connection are all located in the inner layer of 15 the retina, and derive virtually all of their blood supply (i.e., including energy, oxygen/carbon dioxide, and metabolic by-product exchange) from the locally auto regulated retinal circulation. Any significant compromise to the retinal circulation is typically accompanied by visual loss. 20 The vast majority of the eye's inner circulation, on the other hand, passes through the uveal system, a sponge-like, erectile tangle of vessels that lies behind the retina and its pigment epithelium. This vascular bed provides a rich supply of nutrients to the metabolically active photoreceptors of the outer retina, and the pigment epithelium which supports them. Moreover, this seemingly excessive blood supply acts as a heat sink to 25 absorb thermal energy from focused light which could otherwise damage neural tissues. The choroidal circulation, the part of the uveal vascular bed lying directly behind the retina, has some local regulation characteristics, but is also supplied with autonomic nerves capable of producing major changes in circulatory volume in response to stimuli, not necessarily generated in the eye itself. 30 To address retinal and optic nerve blood flow velocity, it is important to understand that the retina is essentially a specialized part of the brain, and its circulation fl Y T n ' Tr r Tr Tr T Tr I C YY T 1 1 '1 T " / T TY TIr 71- i WO 01/10406 PCT/USOO/21929 3 is very tightly regulated. Blood flow through the brain is typically constant in healthy individuals, whether running a marathon or sleeping. Obviously, huge variations in the inflow pressure of carotid artery blood to the brain occur throughout a typical day, and the vasculature in the cerebral cortex responds by adjusting its resistance. This is 5 accomplished by constriction or dilation of the vessels throughout the brain. If the cerebrospinal fluid pressure is increased, creating, in effect, a stiffer vascular bed in the cerebral cortex, the blood vessels in the brain dilate to reduce intrinsic resistance, maintaining constant blood flow. This process is called autoregulation. 10 Autoregulation in the retina is analogous to that found in the brain, so if intraocular pressure is reduced, circulation in the retina is not necessarily increased. This point is clearly illustrated as a coincidental feature of the examples of hyperventilation (to blow off carbon dioxide and thereby reduce circulation to all the intrinsic vessels of the eye) and treatment with latanoprost (increasing the flow of clear fluid out of the eye), 15 which both produce significant reduction of intraocular pressure, but with which visual function may actually be simultaneously diminished. Circulation in the retina also is highly pH-dependent. Studies in which various gases are introduced via the respiratory system into the blood stream clearly demonstrate 20 that as the CO 2 level increases and pH decreases, circulation to the retina typically increases by upward of 40% from the baseline level observed during breathing of atmospheric air. Conversely, breathing pure oxygen produces a profound decrease in circulation in the retina. This latter response may be in part responsible for the disease process known as retrolental fibroplasia, or retinopathy of prematurity, which causes total 25 or partial blindness in many premature infants. In healthy eyes, because of the choroid's relative abundance of vessels, fairly large changes in choroidal blood flow may be accompanied by minimal visual function change. However, because the uveal circulation comprises a significant portion of the 30 ocular volume, a substantial drop in choroidal blood flow is generally accompanied by a significant decrease in intraocular pressure. Thus, during hyperventilation for example, when the natural vasodilator carbon dioxide is blown off, both choroidal and retinal C T T 1D C TTTT T U T D Y TY II WO 01/10406 PCTIUS0O/21929 4 circulation decrease in tandem, and visual function diminishes correspondingly. Typically, an individual with a large intraocular pressure decrease consequent to hyperventilation would have a very large visual function deficit. 5 It has, therefore, become increasingly apparent that blood flow in the retina and about the optic nerve plays a critical role in a number of ocular disorders. New technologies have facilitated a more thorough examination of the posterior aspect of the eye and the evaluation of circulatory, metabolic, and hematologic factors, thereby being better able to determine the causes of various eye diseases. In turn, various therapeutic 10 agents may be applied to more precisely address the pathophysiology underlying specific ocular disorders, more particularly, those ocular disorders whose progression may be attenuated, ameliorated, or reversed by improving ocular circulation. For example, others have used drugs to stimulate cyclic 3', 5'-adenosine 15 monophosphate (cAMP) production, thereby decreasing intraocular pressure and increasing ocular circulation. It is well known that beta-adrenergic impulses in several tissues are mediated intracellularly by a second messenger, cAMP. cAMP is produced from ATP by a membrane bound enzyme, adenylate cyclase. cAMP is believed further to activate steps in a chain of processes leading to protein phosphorylation and final 20 biologic activity. Generally, it is thought that the cAMP step is a process of short duration because cAMP is rapidly and efficiently degraded intracellularly by cAMP phosphodiesterases, which are present in abundance. The pathway by which cAMP is produced is quite complex. cAMP is produced 25 when adenylate cyclase is activated through the activation of many receptors. This stimulation is mediated by G, and by inhibition of at least one other protein belonging to the Gi class of G proteins. It is known that there are at least ten tissue-specific adenylate cyclase isozymes, each having a unique pattern of regulatory responses. Some of these isozymes are inhibited by G protein py subunits, others are stimulated by these subunits if 30 concurrently stimulated by the a subunit of Gs, others are stimulated by Ca2+ or Ca2+_ calmodulin complexes. Adrenergic drugs mediate the production of cAMP, thereby decreasing intraocular pressure and increasing vascular blood flow. C' T C' YIT T1 T T 1ET C YY mT /7TIT 1 VIL\ WO 01/10406 PCTIUSOO/21929 5 In general, diseases which may be amenable to treatment with agents capable of modulating ocular blood flow include, but are not limited to, optic nerve disease, retinal disease or choroidal disease. More specific disorders include, but are not limited to, 5 macular edema or macular degeneration. Macular edema, for example, is defined as swelling within the retina in the critically important central visual zone at the posterior pole of the eye. An accumulation of fluid tends to distract the retinal neural elements from one another and from their local blood supply, creating a dormancy of visual function in the area. Usually, the process is self-limiting, but occasional permanent 10 visual disability results from macular edema. Often times, the swelling may take many months to clear. The precise mechanism by which swelling is triggered is uncertain, but it is probable that certain natural metabolic toxins may play an important role in the disease process. Macular swelling also may follow the insertion of artificial lens implants and cataract surgery, particularly if there is a breach in the lens capsule which 15 segregates the vitreous gel from the fluid-filled anterior chamber. Longstanding macular edema after cataract surgery is one of the most frustrating dilemmas in all of ophthalmology, and is remarkably common. Macular edema is a common and alarming ocular problem, for which no useful form of ocular therapy has been previously known. Two types of cystoid macular edema are: (a) those without vascular leakage: retinitis 20 pigmentosa and other pigmentary retinal degenerative disorders, early stage macular hole, and choroidal neovascularization; and (b) those with vascular leakage: diabetic retinopathy; branch retinal vein occlusion; intermediate uveitis; and ideopathic retinal telangiectasis. 25 Another even more common chronic condition is macular degeneration. Instead of fluid accumulating in the outer retina, hard accumulations of lipofuscin, a metabolic waste product, tend to accumulate between the photoreceptors and the villi of the retinal pigment epithelium. These accumulations gradually enlarge, and in their early pathologic phase create discrete accumulations known as drusen. The lipofuscin is believed to 30 accumulate as a result of the breaking off of the photoreceptor elements. Shedding of the cellular components of the photoreceptors is constantly occurring in a healthy retina. Good retinal pigment epithelial metabolism generally ensures a rapid clearance of such SY T In C T T T T T T V C YL V V IDT TI V '\ WO 01/10406 PCT/USOO/21929 6 catabolic by-products of vision. The accumulation of this waste material retards the interaction between the retina and the retinal pigment epithelium from which nutrients arrive and through which catabolites are cleansed, establishing a self-perpetuating cycle of catabolite accumulation. The accumulations not only block metabolic transfer 5 between the retina and retinal pigment epithelium, they actually continue to undergo photoresponsive metabolism, constantly wasting precious NADH reducing power with no benefit. Improved local circulation might retard or prevent the accumulation of lipofuscin 10 and break the cycle of progressive blockage and waste of metabolic products passing to and from the retina. As drusen accumulate in number and begin to coalesce, vast areas of retinal photoreceptors may become permanently disengaged from their neighboring retinal pigment epithelial villi. The sections of retina so affected become blind. Unfortunately, the greatest propensity among the aging population is for drusen to 15 accumulate in the very central area of vision, the macula. Thus, macular degeneration is the most common cause of legal blindness in the United States and Europe. Whereas macular edema generally affects only one eye, macular degeneration typically involves both eyes and is usually fairly symmetric in its presentation and progression. The problem is on the rise, and is expected to continue to mount. 20 Obviously, normal metabolism tends to produce catabolic waste with accumulation of protons and CO 2 . Many chronic diseases of the ocular tissues tend to stagnate local metabolism and the normal catabolites which would otherwise 'recruit' increased local circulation, are actually not produced. Instead, tissue breakdown products 25 accumulate producing a vicious cycle of degredation without replenishment. Thus, a variety of agents capable of enhancing local circulation in this situation could help clear tissue breakdown products and stimulate a restoration of normal metabolic function. SUMMARY OF THE INVENTION 30 The present invention provides a method for treating an optic nerve disease by increasing ocular blood flow, perfusion and/or circulation. Ocular blood flow is C T I " T T rT T T T y T T' T' T /T-bT T T '% Z WO 01/10406 PCT/USOO/21929 7 generally improved by applying a pharmacologically effective amount of an agent that enhances ocular vascular blood flow either directly to the eye or systemically. As used herein, the phrase "agent that enhances ocular vascular blood flow" refers to cyclic-GMP analogs, agents that inhibit cyclic-GMP phosphodiesterase(s) (PDE), agents that increase 5 the activity of guanylate cyclase, agents that increase levels of cyclic-GMP, or agents that increase levels of nitric oxide (NO) in the tissues of the eye. For example, agents that either enhance the production or increase the availability or longevity of NO, thereby activating guanylate cyclase, would increase levels of cyclic-GMP and cause an increase in ocular blood flow. 10 In preferred embodiments, the optic nerve disease to be treated includes but are not limited to normotensive excavatory optic neuropathy, ischemic optic neuropathy, toxic optic neuropathy, traumatic optic neuropathy, or idiopathic optic neuropathy. Examples of normotensive excavatory optic neuropathy include primary optic atrophy, 15 ocular ischemic syndrome, shock-associated optic atrophy or chronic systemic hypotension. Examples of ischemic optic neuropathy include anterior ischemic optic neuropathy, posterior ischemic optic neuropathy, giant cell arteritis, or Foster-Kennedy syndrome. Examples of toxic optic neuropathy include drug induced optic neuropathy or nutritional optic neuropathy. Examples of traumatic optic neuropathy include 20 inflammatory optic neuropathy or neuroretinitis. Examples of idiopathic optic neuropathy include optic nerve drusen or benign intracranial hypertension. In certain aspects of the present invention, multiple optical nerve diseases occurring in the same patient are treated using the compositions and methods of the invention. 25 Alternatively, the invention provides methods for treating retinal disease by administering a composition comprising an agent that enhances ocular vascular blood flow to a patient suffering from a retinal disease or applying the composition directly to the affected eye. In certain aspects, the retinal disease to be treated may be retinal neovascularization, ischemic hematologic/rheologic disorders or toxic maculopathy. 30 Examples of retinal neovascularization include a diabetes related form of retinal neovascularization, hemoglobinopathy or inflammatory vascular narrowing. The diabetes related form of retinal neovascularization is may be, for example, diabetic C YTr n Y TY T T T T' L1 Yl T' r /TbTTY r T'C\ WO 01/10406 PCT/USOO/21929 8 macular edema, ischemia and neovascularization or non-proliferative diabetic retinopathy. An example of hemoglobinopahy is sickle cell trait. Examples of inflammatory vascular narrowing include lupus, collagen vascular diseases, HIV retinopathy, CMV retinopathy or sarcoidosis. Examples of ischemic hemotologic/ 5 rheologic disorder include central retinal vein occlusion or branch retinal vein occlusion. Examples of toxic maculopathy include drug related maculopathy or chloroquine retinopathy. In certain aspects of the present invention, multiple retinal diseases occurring in the same patient are treated using the compositions and methods of the invention. 10 In certain other preferred methods of the invention, choroidal disease is treated by applying a therapeutically effective amount of a composition comprising at least a first agent that increases ocular blood flow to an affected eye. Examples of choroidal disease include, but are not limited to, an ischemic disorder of the posterior choroid, degenerative 15 subretinal neovascularization, diabetic choroidal ischemia, inflammatory subretinal neovascularization, or non-age related choroidal ischemia. Examples of ischemic disorder of the posterior choroid include degenerative drusen of the macula (i.e. dry age related macular degeneration), macular retinal pigment epithelial atrophy, and retinal pigment epithelial detachment. An example of degenerative subretinal 20 neovascularization is wet age related macular degeneration. Examples of diabetic choroidal ischemia include diabetic choroidopathy. Examples of inflammatory subretinal neovascularization include presumed ocular histoplasmosis syndrome. Examples of non age related choroidal ischemia include myopic degeneration or high myopia. In certain aspects of the present invention, multiple choroidal diseases occurring in the same patient 25 are treated using the compositions and methods of the invention. Of course, patients often present with multiple forms of any of the above diseases and the compositions and methods described herein are effective for treatment of multiple disorders in the same patient. For example, the compositions and methods 30 described herein are useful for treating a patient suffering from an optical nerve disease and a retinal disease. L TT D C r T rT TT T U c Li r T DTTP V 19 WO 01/10406 PCT/USOO/21929 9 The methods of the invention are further effective for the treatment of macular disorders such as macular edema, macular degeneration, drusen, macular disorders related to hypertension, angioma, papillitis, neuroretinitis or pigmentary retinal degenerative disorders, toxic maculopathy and maculopathy secondary to rheologic 5 abnormalities. The methods of the invention are useful for treatment of macular edema with or without vascular leakage. Examples of macular edema without vascular leakage include retinitis pigmentosa, pigmentary retinal degenerative disorder, early stage macular hole, or choroidal neovascularization. Examples of macular edema with vascular leakage include diabetic retinopathy, branch retinal vein occlusion, intermediate 10 uveitis or ideopathic retinal telangiectasis. The methods of the invention may also be used to inhibit or prevent the accumulation of lipofuscin in an eye. In the methods of the invention described above, the agent to be included in the composition is a cyclic-GMP analog, a compound that inhibits cyclic-GMP PDE(s), a 15 compound that activates guanylate cyclase, or a compound that increases levels of cyclic GMP. Preferred cyclic-GMP analogs include 8-bromoguanosine-3,5-cyclic monophosphate. Preferred agents that inhibit cyclic-GMP PDE(s) include sildenafil citrate, dipyridamole, zaprinast, filaminast, denbufyllene, piclamilast, or zardaverine, carboline derivatives, pyridocarbazole derivatives, or quinozolinone compounds. In 20 certain preferred aspects, the PDE inhibitor is selective for PDE type 5 (PDE5) or PDE type 6 (PDE6). Preferred agents that activate guanylate cyclase (by increasing levels of NO) include sodium azide, sodium nitrite, hydroxylamine, hydrazines, nitroglycerine, nitroprusside, nitrosureas or nitrosamines. By activating guanylate cyclase, these agents also increase levels of cyclic-GMP. NO levels may also be increased by NO donors or 25 NO synthase stimulators and such compounds are useful in the compositions for use in the methods of the invention. Preferred NO donors include sodium nitroprusside, nitroglycerine, SIN-1, isosorbide mononitrate, isosorbide dinitrate, diethylenetriamine/NO, glycerol trinitrite, pentaerytrityl tetranitrite, mannitol hexanitrite, inositol hexanitrite or propatyl nitrate. Preferred NO synthase stimulators include 2-aryl 30 p-thiophens. Other preferred compounds include nitrosated and/or nitroxylated PDE inhibitors or polymeric material that releases NO. Combinations of two or more of the agents listed above are also contemplated in certain aspects of the present invention. 0 TT D C T T T TT T' U c u r r T PDTTT V 14 WO 01/10406 PCT/USOO/21929 10 Preferred methods of application include oral and parenteral (including ophthalmic, transdermal, pulmonary, nasal, buccal or sublingual). More specifically, the compositions may be administered by way of a solution, gel, semisolid, suspension, 5 metered dose device, transdermal patch or film. Another aspect of the invention provides a kit for treatment of ocular disorders including a sealed container housing a composition comprising an agent that increases ocular vascular blood flow and instructions for administering the composition to a patient 10 suffering from an ocular disorder such that the patient's ocular blood flow is increased. The compositions included in the kit of the invention include agents as described above. The present invention also provides an effective treatment for maintaining the health of the eye and effectively treating various other ocular conditions by improving 15 ocular blood flow in the retina and choroid of the eye and in and about the optical nerve. In addition to the indications above, the present invention contemplates administration of the compositions described herein to subjects with normal vision for the purpose of increasing visual function including but not limited to visual acuity, 20 contrast sensitivity and perimetric light sensitivity. BRIEF DESCRIPTION OF THE DRAWINGS The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better 25 understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein. FIG. 1A is a graph of retinal blood flow as measured by Heidelberg Retinal Flowmetry (HRF) for three test subjects over time. 30 SY T n T T T1 T T TTr' I Tr T' Tf I TT 1V1\ WO 01/10406 PCT/USOO/21929 11 FIG. 1B is a graph of retinal blood velocity as measured by Heidelberg Retinal Flowmetry (HRF) for three test subjects over time. FIG. 2A is a graph of 4.26 SF cpd contrast sensitivity (visual function) for 5 two test subjects over time. FIG. 2B is a graph of 8.53 SF cpd contrast sensitivity (central macular visual function) for two test subjects over time. 10 FIG. 3A provides Humphrey Frequency Doubling Technology (FDT) visual field reports for a first test subject baseline (left) and post-application (right) conditions. FIG. 3B provides Humphrey Frequency Doubling Technology (FDT) visual field reports for a second test subject baseline (left) and post-application (right) 15 conditions. FIG. 4A is a graph of pulsatile ocular blood flow (OBF) for two test subjects over time. 20 FIG. 4B is a graph of intraocular pressure measured concomitantly with OBF for two test subjects over time. FIG. 5A is a graph of blue field density (perimacular retinal capillary circulatory volume) for two test subjects over time. 25 FIG. 5B is a graph of blue field mean velocity (perimacular retinal capillary circulatory speed) for two test subjects over time. FIG. 6A Humphrey visual field tests, showing extent of the perpetual 30 progression of field loss despite maintaining intraocular pressures (IOP) from 6-10 mmHg without medication. Pericentral thresholds clockwise from superionasal were 26, 26, 14, and 25 dB. 1 Y T n T T TTTU CITU 11 V T /D T TT V '14 WO 01/10406 PCT/USOO/21929 12 FIG. 6B Clockwise progression of pericentral threshold values was 28, 29, 23, and 26 dB, a mean increase of 3.75 decibels for the macular region loci, nearly a tenfold increase in light sensitivity. 5 FIG. 7A Humphrey 10-2 visual field test, prior to and one hour after ingestion of 50 mg oral sildenafil. FIG. 7B Humphrey visual field test showing visual thresholds of 26, 28, 10 and 27 decibels across the central six degrees above the horizontal meridian, and 16 of the 17 superotemporal loci now had positive thresholds, 15 of which were in double digits. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT 15 1. Enhanced Blood flow For Treatment of Ocular Disorders Surprisingly, agents that enhance blood flow to and around the optic nerve have been found to be useful in treating a number of eye disorders. It is known that relatively 20 large changes in choroidal blood flow may be accompanied by minimal visual function change. However, retinal circulation is very tightly regulated within the brain. The majority of the eye's inner circulation passes through the uveal system, lying behind the retina and its pigment epithelium. Choroidal circulation is part of the vascular bed lying directly behind the retina and contains autonomic nerves capable of producing major 25 changes in circulatory volume in response to stimuli, which may be generated within the eye or outside of the eye. While the vision process is quite complex, it is believed that the signal carried by the retina, the optic nerve head, and the optic nerve fibers is the most crucial part of the 30 process. Adequate blood flow nurtures the tissue along this path and assures transport of the signal. Many ocular disorders are known to involve some kind of blockage of or hindrance to optic blood flow. 0 Y T C Tr T T T T T 1 C 1I U VT /DT TT1 V I\ WO 01/10406 PCT/USOO/21929 13 The human choroid, which supports the metabolic function of the outer retina, is an erectile tissue, analogous in certain respects to the corpus cavernosum. The fenestrated choroidal vasculature is highly responsive to both local and neurogenic 5 stimuli, and the uveal system of which it is part may hold up to 98% of the intraocular blood volume. Choroidal blood flow has recently been reported to be decreased in macular degeneration, the leading cause of acquired blindness in North America. The inventor reasoned that agents capable of modulating ocular blood flow would be of therapeutic value in the treatment of a range of choroidal, retinal, and axonal disorders, 10 provided circulatory augmentation can be achieved without debilitating metabolic compromise or vascular leakage. There are a number of ocular disease states in which increasing ocular blood flow is beneficial. The methods of the invention include administering agents that increase 15 ocular blood flow to a patient suffering from such an ocular disease state. Table 1 sets forth a number of the disease states that would benefit from treatment using the methods of the present invention. Q T I TTTT IT 1 T 1 T PITTT r \ WO 01/10406 PCT/US0O/21929
CL
r0 E CL C)) (3) -) CL -a tC) cq 2 N CL L) r. C)) - dc - 4-.E - -C8 a) '-C _ C -- > > ) . 0 o C0 CwC 0 C.. HCC 3d~C, 4, C>~~4 C C) CCQ) .9 U, *~ o.9 > 03 E ) C CO/ ~ 3 > o~ 8 Cd 0 0 t E C) 2 ) . .2 bt "C Q -0 -C,3 E C) . 0 cz~ Ec b U)~~~ N . 0 c $-. .~C 2 2 u~ -S cz > CC. CC C)
-
3- 0 z > m aC CAz L. C , . >. In 0C Ql >0 = 0 -L d ca u 0C 0 E c" vC = CC3 C u as CC) 3-C Zo C.) 0 C. O.2 Q d Z .0 WO 01/10406 PCT/USOO/21929 15 As illustrated in Table 1 (not intended to be exhaustive), there are generally three broad categories of optic disease states for which increased ocular blood flow is beneficial. Those are optic nerve disease, retina disease and choroidal disease. Within 5 those general categories are a number of additional categories with more specific examples provided for illustration. Of course, those skilled in the art would understand that other disease states in which ocular blood flow is a factor would benefit from treatment using the methods of the invention. The benefits of the present invention are described in more detail below using a specific type of choroidal disease, age related 10 macular degeneration, for illustration purposes only. It will be understood that the present methods and compositions are useful for the treatment of any optic disease state. Age-related macular degeneration (ARMD) is the leading cause of visual loss among Americans over 60 years of age. As the macula degenerates, central reading 15 vision deteriorates while peripheral vision is rarely affected. There are two forms of ARMD, dry or atrophic ARMD, and wet or exudative ARMD. Wet ARMD is associated with abnormal blood vessel growth (subretinal neovascularization) and accounts for a high proportion of the most severe visual destruction encountered among ARMD patients. Wet ARMD, however, only accounts for 10% of ARMD cases. Because of its 20 dramatic pathologic course, wet ARMD has received much attention, and numerous treatment modalities have been devised to abate this form of the disease, most of which are directed toward destroying the invading, leaky blood vessels by laser or other means. Dry ARMD is far more prevalent, progresses more slowly, and accounts for 90% of ARMD cases. Advanced cases of dry ARMD constitute a high proportion of individuals 25 declared legally blind in the United States, Europe, Australia, and parts of Asia. In addition, a high proportion of wet ARMD cases begin as dry ARMD. Despite the long felt need for effective treatments for dry ARMD, none were available prior to the present invention. 30 The circulation of blood through vessels underlying the retina, in the choroid, is compromised in patients afflicted with ARMD (Pauleikboff et al. 1990; Chen et al. 1990; Giovannini et al. 1994; Grunwald et al. 1994; Friedman et al. 1995; Ross et al. C' Y T " C' T Yr TY T T r Ir L' TI Ir T /Dr f'lTI T 114l WO 01/10406 PCTIUSOO/21929 16 1998; Ciulla et al. 1999; Dontsov et al. 1999). Because the choroid provides the only source of nourishment for the photoreceptors in the outer retina, and the only means for removing waste products, this decrease in circulation can have dire effects on the macula, one of the body's most metabolically active tissues. 5 In ARMD, accumulation of lipofuscin, an aggregate of breakdown products from the outer retina, occurs in the interspace between the retinal photoreceptors and the villiform pigment epithelial cells with which they interdigitate. The retinal pigment epithelium (RPE) is a vital metabolic factory, which reprocesses photopigment and 10 carries out many critical support and transport processes, maintaining retinal function. The outermost layer of the anatomic sandwich supporting retinal function is the choroid, a highly vascular tissue which supplies nutrients to and which clears catabolites from this highly active tissue complex. Lipofuscin builds up in the interface between the RPE and choroid in diseased eyes. Incompletely-degraded, lipofuscin-bound pigmentary debris 15 which accumulates in this space in ARMD constantly seizes and oxidatively wastes molecular energy passing from the choroid to the RPE, even in the absence of light (Sponsel et al. 2000). Therefore, ARMD, once established, tends to follow a vicious pathologic spiral, selectively afflicting the zone of highest metabolic activity, the macula. 20 Other major sources of blindness, wet ARMD, myopic degeneration, or diabetic retinopathy, are characterized by the formation of abnormal vessels behind or within the substance of the retina. The new, abnormal vessels which typify these conditions proliferate through the action of locally-released hormonal agents, which are released in response to attenuated circulation within the eye. Such vessels, even after they form, are 25 only sustained by persisting circulatory inadequacy in the surrounding tissue. Normalization of the balance between metabolic tissue demand, nutrient provision, and catabolite clearance results in the regression of these leaky and potentially blinding anomalous vessels. Therefore, the present methods and compositions that increase blood flow in the retina and choroid are expected to be of benefit in treating the latter stages of 30 wet ARMD and proliferative diabetic retinopathy. In addition, timely treatment of at-risk individuals with preproliferative diabetes and dry ARMD, as described herein, is expected to prevent progression to the neovascular stages of these diseases. r TR S TITJTE SHEET (RULE26) WO 01/10406 PCT/USOO/21929 17 2. Agents That Enhance Blood flow 5 The present invention is grounded on the discovery that increasing ocular blood flow, particularly in the retina of the eye is a safe and effective way to maintain the health of the eye and to treat various ocular disorders that have in their etiology inadequate vascular blood flow, such as macular edema and macular degeneration. While the 10 precise theory is not completely understood, improved (i.e., increased) blood flow in and to the retina and choroid of the eye can greatly improve retinal and optic nerve health which, in turn, effectively combats macular edema, macular degeneration, and other ocular disorders. 15 It is known that the enzyme guanylate cyclase catalyzes the conversion of guanidine triphosphate (GTP) to cyclic-GMP. When guanylate cyclase is activated, cyclic-GMP levels increase. Murad et al. used nitrogen containing compounds, such as sodium azide, sodium nitrite and hydroxylamine, to activate guanylate cyclase and discovered that these compounds are converted to an active intermediate, nitric oxide 20 (NO), that is directly involved in the activation of guanylate cyclase and the subsequent conversion of GTP to cyclic-GMP. Thus, agents that activate guanylate cyclase through the formation of the intermediate NO, thereby increasing NO levels and, subsequently, increasing cyclic-GMP levels, and increasing ocular vascular blood flow, are particularly useful in the methods of the present invention. The compositions of the invention may 25 include more than one agent that activates guanylate cyclase. As mentioned above, cyclic-AMP is also known to increase vascular blood flow, however, it operates through a significantly different pathway than that of cyclic-GMP. In short, certain adrenergic drugs mediate the production of cyclic-AMP, thereby 30 decreasing intraocular pressure and increasing vascular blood flow. Therefore, this mechanism of action is significantly different from the pathway followed by cyclic-GMP in the stimulation of ocular vascular blood flow as described herein. L' Y T " CYT1rf T T T T T Ir iT TTT i \ WO 01/10406 PCTUSOO/21929 18 Besides the agents that activate guanylate cyclase, such as sodium azide, sodium nitrite, or hydroxylamine, discussed above, other agents that activate guanylate cyclase, increase NO levels and/or increase cyclic-GMP levels also would increase ocular blood 5 flow and improve vision. Other guanylate cyclase activators include hydrazines, nitroglycerine, nitroprusside, nitrosureas and nitrosamines. Agents that increase NO levels include those agents that are nitric oxide donors, stimulate nitric oxide synthase or increase availability or longevity of nitric oxide. 10 Agents that stimulate nitric oxide synthase include 2-aryl-p-thiophens, described for example, in U.S. Patent No. 5,811,437. incorporated herein by reference or other compounds described, for example, in U.S. Patent No. 5,478,946, incorporated herein by reference. Agents that are nitric oxide donors include sodium nitroprusside, nitroglycerine, SIN-1, isosorbide mononitrate, isosorbide dinitrate, 15 diethylenetriamine/NO, glycerol trinitrite, petnaerytrityl tetranitrite, mannitol hexanitrite, inositol hexanitrite, or propatyl nitrate. Other compounds useful in the compositions of the invention include nitrosated and/or nitrosylated PDE inhibitors (as described, for example, in U.S. Patent Nos. 5,958,926 and 5,874,437, each incorporated herein by reference), or polymeric material that releases NO (as described, for example, in U.S. 20 Patent Nos. 5,994,444 and 5,770,645, each incorporated herein by reference). The compositions of the invention may include more than one agent that increases NO levels. It is also known that inhibition of cyclic-GMP PDE(s), especially inhibition of PDE type 5 and type 6, promotes an increase in levels of cyclic-GMP (cGMP), which in 25 turn fosters an increase in blood flow in the uveal system. This is characterized by increased blood flow velocity in the retina and the tissue surrounding the optic nerve. Thus, agents that inhibit cyclic-GMP PDE(s) also are useful in the methods of the present invention. The compositions of the invention may include more than one inhibitor of cyclic-GMP PDE(s). 30 Zaprinast and dipyridamole are both known to be inhibitors of the type 5 PDE family and would, therefore, be expected to act to increase ocular blood flow in the C TT D C T T Tr IT T T c J r rT (DTT r it' \ WO 01/10406 PCTUSOO/21929 19 methods of the present invention. Other PDE inhibitors useful in the methods of the invention include filaminast, denbufyllene, piclimalist, pentoxyfilline, carboline derivatives (as described, for example, in U.S. Patent No. 6,043,252, incorporated herein by reference), pyridocarbazole derivatives (as described, for example, in U.S. Patent No. 5 6,018,046, incorporated herein by reference) or quinozolinone compounds (as described, for example, in U.S. Patent No. 6,087,368, incorporated herein by reference). It will also be understood that the compositions of the invention may include a combination of any of the above described agents. 10 The following more detailed discussion of a particular preferred compound for use in the methods of the present invention is provided for illustration purposes only and is not meant to limit the scope of the invention. Those skilled in the art will recognize that agents described above, and other agents that act similarly, are useful in the methods 15 of the invention. A particularly preferred compound for use in accordance with the present invention is sildenafil (preferably the citrate salt). Sildenafil is known to cause smooth muscle relaxation and an increase in blood flow, and is a selective inhibitor of cyclic 20 guanosine monophosphate (cGMP)-specific PDE type 5 (PDE5). Sildenafil citrate is designated chemically as 1-[3-(6,7-dihydro-l-methyl-7-oxo-3-propyl-1 H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyp henyl] sulfonyl-4-methylpiperazine citrate and has the following structural formula: t VT Y w ' T 'Y TT 'T' Y' C YY Yr' Y' 'T' /TYTT T' 'I\ WO 01/10406 PCT/USOO/21929 20 0 CH3 CH3CH20 FNN CH2CH 2
CH
3 COH 02S HOOC OH N -CO 2 H N
CH
3 Sildenafil citrate is a white to off-white crystalline powder with a solubility of 3.5 mg/mL in water and a molecular weight of 666.7. Sildenafil citrate has most recently 5 been utilized as the basis for an oral therapy for erectile dysfunction and has been marketed by Pfizer Labs under the trademark Viagra®. Publications relating to benign visual side-effects (e.g., blue-shift in vision, light-sensitivity, and blurring noted to occur in some patients) of sildenafil prompted the FDA to insist on product insert warnings. 10 In spite of these side effects, the inventor hypothesized that sildenafil might be therapeutically beneficial in an appropriate setting. Elevation of cyclic-GMP levels, a potent vasodilator, is brought about by the effect of sildenafil on PDE activity. Appreciating this mechanism (i.e., the local effects of the PDE inhibitor on intracellular cyclic-GMP), and possible centrally-mediated neurogenic effects, the inventor reasoned 15 that sildenafil could conceivably mediate significant increases in choroidal blood flow. Therefore, changes in vision and ocular blood flow were evaluated among a dozen clinician volunteers before and after taking a single 50 mg oral dose of sildenafil. It was revealed that both choroidal circulation and high resolution central visual function were substantially increased by oral sildenafil. 20 C Y T T ' T /1 TT Yr T' TI 71 r' ' TIrbTY TY Y' i \ WO 01/10406 PCT/USOO/21929 21 There were significant increases in pulsatile ocular blood flow (+29 percent; from 916 +/-103 to 1185 +/-158 pl/min; p 0.02) and contrast sensitivity (+34 percent; from 92 +/-1 Ito 122 +/-11 log units; p:0.0 1), 110 +/- 8 min after sildenafil administration. Retinal microcirculation increased in 7 of the 9 eyes in which there were stable scans (+8 5 percent; p:0.09). The results of perimetry did not change significantly, nor did mean systolic and diastolic blood pressure, systemic pulse amplitude, and intraocular pressure. None of the subjects reported any subjective visual symptoms (Sponsel et al. 2000). Pulsatile ocular blood flow occurs as a result of cardiac-synchronous filling of the 10 choroidal circulation, in which the majority of the ocular blood volume is found. The increase in pulsatile choroidal blood flow after sildenafil administration was probably due to dilatation of the choroidal vessels, because there were no changes in intraocular pressure or systemic pulse amplitude, other major determinants of choroidal blood flow. 15 The mechanism associated with sildenafil citrate's use as a therapy for erectile dysfunction may explain its efficacious use in the methods of the present invention. The physiologic mechanism of erection of the penis involves release of nitric oxide (NO) in the corpus cavernosum during sexual stimulation. NO then activates the enzyme guanylate cyclase, which results in increased levels of cyclic guanosine monophosphate 20 (cGMP), producing smooth muscle relaxation in the corpus cavernosum and allowing inflow of blood. Sildenafil has no direct relaxant effect on isolated human corpus cavernosum, but enhances the effect of nitric oxide (NO) by inhibiting PDE type 5 (PDE5), which is responsible for degradation of cGMP in the corpus cavernosum. When sexual stimulation causes local release of NO, inhibition of PDE5 by sildenafil causes 25 increased levels of cGMP in the corpus cavernosum, resulting in smooth muscle relaxation and inflow of blood to the corpus cavemosum. Studies in vitro (by Pfizer) have shown that sildenafil is selective for PDE5. Its effect is more potent on PDE5 than on other known PDEs (>10-fold for PDE6, >80-fold 30 for PDEI, >1,000-fold for PDE2, PDE3, and PDE4). The approximately 4,000-fold selectivity for PDE5 versus PDE3 is important because PDE3 is involved in control of cardiac contractility. C Y T T" C T T T T T T T' TT T T'T /TTTY T'i\ WO 01/10406 PCT/USOO/21929 22 3. Formulations for Use in Treatment of Ocular Disease States Agents for use in the methods of the present invention may be delivered orally, 5 parenterally, or may be formulated for direct topical application to the eye. The use of the term "applying" herein refers to any of the methods of delivery, including orally, parenterally, topically or otherwise. These delivery systems are effective to administer the compositions for use in the methods of the invention to the eye for the purpose of increasing optical nerve and retinal blood flow velocity. It will be appreciated that in 10 accordance with the invention, the compositions can be administered by way of a solution, gel, semisolid, suspension, metered dose device, transdermal patch or film. Other means of delivery are also contemplated. The routes of administration of sildenafil citrate, for example, are typically oral and parenteral (including ophthalmic, transdermal, pulmonary, nasal, buccal, sublingual). 15 Preferred compositions for use in the methods of the present invention will typically, but not necessarily, comprise a solution, gel, semisolid, suspension, metered dose device, transdermal patch or film including, for example, an agent that enhances ocular blood flow, a buffer system (e.g., hydrochloric acid, sodium hydroxide, boric acid, 20 sodium borate, acetic acid, sodium acetate, sodium biphosphate, monobasic sodium phosphate, dibasic sodium phosphate, sodium carbonate, sodium acid phosphate, disodium phosphate, sodium thiosulfate; 0.1 - 5 % of each, or the like), a preservative system (e.g., benzalkonium chloride 0.01 - 5%, benzethonium chloride 0.01 - 5%, chlorobutanol 0.01 - 5%, methylparaben 0.01 - 5%, propylparaben 0.01 phenylmercuric 25 acetate 0.01 - 5%, phenylmercuric nitrate 0.01 - 5%, thimerosal 0.01 -sorbic acid 0.01 5%, sodium perborate 0.01 - 5%, benzvl alcohol 0.01 - 5% or the like), an absorption enhancer system (e.g., polysorbate 80 0.005 - 6%, tocopherol TPGS 0.01 - 10'7c, tyloxapol 0.005 - 6%, or the like), a stabilizer system (e.g., ascorbic acid 0.01 - 5%, tocopherol 0.01 - 5%, disodium ethylenediaminetetraacetate 0.01 - 5%, tetrasodium 30 ethylenediaminetetraacetate 0.01 - 5%, or the like), a surfactant system (e.g., polysorbate 80 0.005 - 6%, tyloxapol 0.005 - 6%, poloxamer 0.5 - 10%, or the like), a viscosity-increasing system (e.g., polyvinyl alcohol 0.5 - 5%, polyethylene glycol 0.5 0 T T n T r T T T'T' C T'Ir T'r /" T YTT1 'IC\ WO 01/10406 PCT/USOO/21929 23 5%, hydroxypropyl methylcellulose 0.5 - 5%, povidone 0.5 - 5%, hydroxyethyl cellulose 0.5 - 5%, methylcellulose 0.5 - 5%, dextran 0.5 - 5%, acacia 0.5 - 5%, white petrolatum 50 - 99.9%, mineral oil 1 - 8%, lanolin I - 8%, propylene glycol 1 - 20%, glycerin 1 20%, carbopol 1 - 10%, carboxymethyl cellulose 0.5 - 5%, lanolin alcohols 0.5 -5%, or 5 the like), a gelling system (e.g., carbopol 1 - 10%, polyvinyl alcohol 0.5 - 5%, hydroxypropyl cellulose 0.5 - 10%, hydroxyethyl cellulose 0.5 - 10%, methyl cellulose 0.5 - 10%, poloxamer 0.5 - 10%, polyacrylamide 0.5 - 10%, hyaluroriic acid 0.5 - 10%, gellan gum 0.5 - 10%, pectin 0.5 - 10%, or the like) , an osmolality adjusting system (potassium chloride 0.2 - 0.9%, sodium chloride 0.2 - 0.9%, magnesium chloride 0.2 10 0.9%, calcium chloride 0.2 - 0.9%, zinc sulfate 0.2 - 0.9%, polyethylene glycol 0.2 0.9%, boric acid 0.2 - 0.9%, or the like) and a vehicle (e.g., water, white petrolatum; 5 99.9% for each). While some compositions for use in the present invention may include all of the 15 above listed elements, other useful compositions may include less than all of the above listed elements, which generally serve to increase stability, storability, storage life, etc. For example, it is contemplated that compositions including a compound that enhances ocular blood flow, i.e., by increasing NO, increasing cyclic-GMP, and/or inhibiting cGMP PDE, with a buffer system and a vehicle may be useful. Alternatively, 20 compositions including a compound that enhances ocular blood flow, with a viscosity increasing system and an osmolality adjusting system may be useful. These examples are intended to be illustrative of certain preferred embodiments and are not meant to be exhaustive or limiting the scope of the invention in any way. 25 A preferred composition contains sildenafil citrate in an oral or ophthalmic preparation such as those described above. For embodiments in which sildenafil citrate is administered orally, the sildenafil citrate will typically be present in amounts ranging from between about 5 mg to about 500 mg per dose. More preferably, the oral dose will contain from between about 10 mg to about 400 mg of sildenafil citrate, or between about 30 15 mg and about 300 mg of sildenafil citrate or between about 20 mg and about 250 mg of sildenafil citrate or between about 25 mg and about 200 mg of sildenafil citrate. Most preferably, the oral dose will contain about 50 to 100 mg sildenafil citrate. It will be V T T " C Tr T T T U L M T DY II K I WO 01/10406 PCT/IUSOO/21929 24 understood that a range, for example of between about 5 mg to about 500 mg, includes all integral amounts within the range, i.e., 6 mg, 7 mg, 8 mg, 9 mg etc., 30 mg, 31 mg, 32 mg, 33 mg, etc., 45 mg, 46 mg, 47 mg, 48 mg, 49 mg, etc., 55 mg, 56 mg, 57 mg, 58 mg, etc., 75 mg, 76 mg, 77 mg, 78 mg, etc. 101 mg, 102 mg, 103 mg, 104 mg, etc., 150 mg, 5 151 mg, 152 mg, 153 mg, etc. 201 mg, 202 mg, 203 mg, 204 mg, etc, 220 mg, 221 mg, 222 mg, 223 mg, etc., 450 mg, 451 mg, 452 mg, 453 mg, etc., 475 mg, 476 mg, 477 mg, 478 mg, 479 mg, etc. Preferred ophthalmic preparations of the present invention will generally include 10 sildenafil citrate, for example, in concentrations of between about .001 % and about 20 % (weight per volume), including all amounts within the range. More preferably, sildenafil citrate will be present in the ophthalmic preparations in concentrations of between about .01 % and 5 % and most preferably, the ophthalmic preparations of the invention will contain about 1% sildenafil citrate. Of course, those skilled in the art will understand that 15 the stated ranges include all amounts within the range, i.e., .02 %, .03 %, .04 %, etc., .1 %, .11 %, .12 %, etc., .2 %, .3 %, etc., 1 %, 1.1 %, 1.2 %, 1.3 %, 1.4 % etc. 4.0 %, 4.1 % 4.2 %, 4.3 %,4.4 %, 4.5 %, 4.6 %, 4.7 %, 4.8 %, 4.9 %, etc., 15 %, 16 %, 17 %, 18 %, 19 % etc. 20 Where desired, a convenient manner to deliver a metered dose is through the use of a device that is pressurized with a propellant system or is delivered by an aqueous pump spray. The propellant system may include 1,1,1,2-tetrafluoroethane (30 -99.9%) and/or 1,1,1,2,3,3, 3-heptafluoropropane (30 - 99.9%) or other known propellants. Where employed, ethanol is typically used as a cosolvent (0.5 - 5%), although other solvents 25 may also be useful in conjunction with the methods of the invention. The preferred median droplet size distribution for the pulmonary pressurized metered dose inhaler is 2 5 microns and the preferred median droplet size distribution for the nasal pressurized metered dose inhaler is 10 - 20 microns. 30 Exemplary processes for formulation include the following: SY T n T 'T T T ' T CT, T YY Tr -r T /YTT I 'IZ\ WO 01/10406 PCT/USOO/21929 25 For the solution formulation, a quantity of an agent that enhances ocular vascular blood flow, such as sildenafil citrate (solubility of 3.5 mg/ml), is dissolved in a portion of the vehicle. The vehicle contains a cosolvent system to increase the solubility of the drug (agent that enhances ocular vascular blood flow) in the vehicle. The pH of the solution is 5 adjusted and the solution is buffered. The solution is preserved and the tonicity is adjusted. The viscosity of the solution is adjusted by adding a viscosity-increasing agent. The final volume of the solution is adjusted using the remainder of the vehicle. The solution is packaged in an appropriate container/closure system to optimize stability of the drug substance and the integrity of the finished product. 10 For the gel formulation, the gelling agent is dissolved into an aliquot of water. In a separate portion of water, the drug, preservative, stabilizer, buffer and osmolality adjusting agent is dissolved. This blend is combined with the gel and stirred until homogeneous. The temperature may be elevated in order to enhance the mixing process. 15 A high shear homogenizer is preferred to prepare the gel formulation. The drug containing gel is packaged in an appropriate container/closure system to optimize stability of the drug substance and the integrity of the finished product. For the semisolid formulation, the vehicle is heated using low heat and the 20 preservatives are added to the molten vehicle mixture. The drug is then incorporated with continuous mixing into the molten vehicle mixture and homogenized at 2500 - 5000 psi. The preparation is removed from the heat source and continuously mixed until congealed at room temperature. The finished semisolid is packaged into an appropriate container/closure system to optimize the stability of the drug substance and the integrity 25 of the finished product. For the suspension formulation, an amount of micronized agent in excess of the solubility (for example, more than 3.5 mg/ml of sildenafil citrate) is added to an aqueous vehicle containing the surfactant system, preservative system, buffer system, osmolality 30 adjusting agent, and a viscosity increasing system. The suspension is homogenized using a high shear mixer (5000 psi pressure) until the drug is uniformly distributed. The finished suspension containing the agent that enhance ocular vascular blood flow, is CIT1RrTTTTTTF SHEET (RULE26) WO 01/10406 PCT/USOO/21929 26 packaged into an appropriate container/closure system to optimize the stability of the drug substance and the integrity of the finished product. It is contemplated that the container/closure system containing the composition 5 will be included in a kit along with instructions for administration effective to increase ocular blood flow. The instructions will typically include directions for dosage, application, frequency and other relevant information pertinent to practice of the methods of the invention. 10 The film formulation (for delivery to the eye, skin, buccal cavity) is prepared by hot melt extrusion, cast film method, or other methods suitable for the formation of thin films. The preferred method is to mix the agent that enhances ocular vascular blood flow, such as sildenafil citrate, with a blend of thermoplastic polymers and hot melt extruding the drug containing mass through a suitable extruder. The thickness of the film 15 is manipulated by the components of the formulation and by the operating parameters of the extruder. The film containing the drug is cut in a suitable size for ophthalmic, buccal or transdermal application, and packaged in an appropriate container/closure system to optimize the stability of the drug substance and the integrity of the finished product. 20 Again, the film packaged in the container/closure system may be included in a kit along with instructions for application of the film effective to increase ocular blood flow, or treat macular disorders, etc., as contemplated by the invention. The instructions will typically include such information as location of application of the film, frequency of application, time period of application, etc. The instructions may be printed on the 25 outside of the container/closure system housing the film or may be included in the kit separately from the film container/closure system. For the pressurized metered dose inhaler, agent that enhances ocular vascular blood flow, such as sildenafil citrate, is mixed with ethanol, to produce a "drug 30 concentrate" and an aliquot of the drug concentrate is dispensed into an epoxy-lined aluminum can (or lined Type I glass vial). The metering valve (20 - 150 microliter preferably) is crimped onto the neck of the can. The propellant system is filled through qTIRqTTTTTTTF SHFET (RULF26) WO 01/10406 PCT/USOO/21929 27 the valve. The canister is mated with an actuator (oral for pulmonary; nasal for delivery to the nose; ophthalmic for delivery, to the eye). Alternatively, the agent that enhances ocular vascular blood flow, such as sildenafil citrate, is administered in a metered dose aqueous dispersion using a pump. The drug is mixed with the surfactant and water. 5 After mixing to dissolve the drug, a viscosity increasing agent is added and the mixture stirred. A preservative system is dispersed and the mixture is stirred. The drug formulation is filled into a container (high density polyethylene) and the pump is screwed on. 10 The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the 15 present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention. EXAMPLE 1 20 A 63 year-old man with dense pericentral visual field loss in the right eye and chronic excavatory optic neuropathy developed a new extension of his right inferiotemporal scotoma on Humphrey 30-2 SITA-standard testing, splitting fixation with a threshold of 14 decibels in the macular zone of that quadrant. The patient had 25 undergone over a dozen prior Humphrey field tests, showing perpetual progression of field loss despite maintaining intraocular pressures (IOP) from 6-10 mmHg without medication. Pericentral thresholds clockwise from superionasal were 26, 26, 14, and 25 dB (FIG. 6A). 30 Shortly after performing visual field and contrast sensitivity testing, the patient took a single 50 mg oral dose of sildenafil citrate (Viagra®), and repeated these visual tests 110 minutes later. There was a dramatic resolution of the pericentral perimetric STR STITITTE SHEET (RULE26) WO 01/10406 PCTUSOO/21929 28 defect, which increased in threshold from 14 to 23 decibels. The clockwise progression of pericentral threshold values was 28, 29, 23, and 26 dB, a mean increase of 3.75 decibels for the macular region loci, nearly a tenfold increase in light sensitivity (FIG. 6B). 5 Central retinal contrast sensitivity measurements carried out before and after sildenafil administration also showed remarkable improvement. Seven-degree sine wave patterns of 1 and 4 cycles per degree (cpd) at 15 reversals per second (Neuro Scientific) were presented pre- and post-sildenafil. Three complete sets of training contrast 10 sensitivity measurements in both eyes were carried out prior to testing. Low threshold values of 5.8 and 44.0, respectively, were obtained at 1 and 4 cpd in the eye with pericentral visual field loss (OD) before the drug was administered. Thresholds in the fellow eye were 10.0 and 92.3, respectively. 110 minutes after oral sildenafil administration, left eye measures remained fairly constant, but those in the eye with the 15 pericentral perimetric defect (OD) increased dramatically to 31.2 and 92.3, respectively, at 1 and 4 cpd. IOP and blood pressure were unaltered. EXAMPLE 2 20 Another patient, an alert, 78 year-old retired professor of vascular surgery, underwent pulsatile ocular blood flow measurements and Humphrey 10-2 visual field analyses prior to and one hour after ingestion of 50 mg oral sildenafil. In his more diseased right eye, the entire superionasal visual field was a nonfunctional absolute scotoma, and 10 of the 17 of the superiotemporal quadrant loci also had thresholds of 25 zero (FIG. 7A). Note the near total absence of visual function in the right superionasal visual field extending into the macular zone. The patient's pulsatile ocular blood flow (POBF) in this eye was already fairly high, 1554 1tl/min. One hour after sildenafil ingestion, his right eye POBF increased to 30 1975 pl/min. The superonasal quadrant, previously blind, now exhibited contiguous loci with visual thresholds of 26, 28, and 27 decibels across the central six degrees above the C TT D C Tr T Tr TT Tr r Q U- r r T PDYTT r '4 WO 01/10406 PCTIUSOO/21929 29 horizontal meridian, and 16 of the 17 superotemporal loci now had positive thresholds, 15 of which were in double-digits (FIG. 7B). EXAMPLE 3 5 Quite clearly, sildenafil citrate, even when administered orally, can positively influence blood flow and visual function for a very brief period of time. Topical application of compositions comprising the drug, yielded similar surprising results: 10 A 45 year-old man with normal visual function, slit lamp and fundus findings underwent Humphrey 10-2 full-threshold central visual field analysis and contrast sensitivity (seven-degree sine wave patterns of 1 and 4 cycles per degree at 15 reversals per second; NeuroScientific) testing. The subject had undergone numerous previous Humphrey field and contrast sensitivity tests, eliminating the prospect of any significant 15 learning effect on repeat testing. Shortly after performing baseline visual field and contrast sensitivity tests, he received in masked fashion one drop of artificial tear solution to his right eye, and one drop of sildenafil solution (sildenafil 1% (10 mg/ml in Schein artificial tear solution 20 buffered to pH 8.0)) to his left eye. He reported no discomfort with either drop. and was unaware which eye had received which agent. He repeated visual function testing in both eyes 100 minutes after receiving the eyedrops. There was a dramatic increase in pericentral contrast sensitivity in the eye 25 receiving sildenafil, while the function of the placebo-treated eye remained relatively constant. Contrast sensitivity (CS) ratios to the 1 cycle per degree stimulus were 203 in the right eye and 235 in the left eye prior to treatment. The placebo-treated right eye had a CS ratio of 235 after 100 minutes, while the sildenafil-treated eye had a CS ratio of 317 (p<0.0001). The increase in CS ratio to the 4 cycle per degree stimulus with sildenafil 30 was similarly impressive, with values of 194 in the placebo-treated right eye versus 581 in the sildenafil-treated left eye 100 minutes after treatment (p<O.0001). qTTR STTTE SHEET (RULE26) WO 01/10406 PCTUSOO/21929 30 Humphrey 10-2 visual fields demonstrated a similar phenomenon. Despite the left eye having a lower light sensitivity than the right prior to treatment, it displayed a significantly higher retinal light sensitivity than the right eye 100 minutes after receiving topical sildenafil. The pre-treatment mean threshold value for the 10 degree visual field 5 in the left eye was 31.2 (+/-.19) decibels; 100 minutes after sildenafil eyedrop application this had increased to 32.7 (+/-.17) decibels (p<0.0001), a 70% increase. Intraocular pressures remained around 10 mmHg in both eyes and did not rise during the study interval. There were no adverse effects or significant visual symptoms elicited, and ocular appearance, pupil diameter. conjunctival and corneal appearance were symmetric 10 and normal in both eyes. EXAMPLE 4 FIG. IA and FIG. lB represent patient data from three patients showing an 15 increase in retinal blood flow and blood velocity as measured using scanning laser doppler velocimetry. The data shows the increase over a period of time up to about 85 minutes from administration of 50 mg oral sildenafil citrate (Viagra*). FIG. lA is a graph of retinal blood flow as measured by Heidelberg Retinal Flowmetry (HRF) for three test subjects over time. FIG. lB is a graph of retinal blood velocity as measured by 20 Heidelberg Retinal Flowmetry (HRF) for three test subjects over time. EXAMPLE 5 FIG. 2A and FIG. 2B represent patient data from two patients showing an increase 25 in contrast sensitivity over a period of time up to about 75 to 125 minutes from administration of 50 mg oral sildenafil citrate (Viagra®). FIG. 2A is a graph of 4.26 SF cpd contrast sensitivity (visual function) for two test subjects over time. FIG 2B is a graph of 8.53 SF cpd contrast sensitivity (central macular visual function) for two test subjects over time. 30 L IT n L T T r TT T U CT L L UT U DTTY V I\ WO 01/10406 PCT/USOO/21929 31 EXAMPLE 6 FIG. 3A and FIG. 3B show an improvement in visual field response for two separate individuals. The reports show both baseline (left side of each figure) and 5 post-administration of 50 mg oral sildenafil citrate (Viagra*). FIG. 3A provides Humphrey Frequency Doubling Technology (FDT) visual field reports for a first test subject baseline (left) and post-application (right) conditions. FIG. 3B provides Humphrey Frequency Doubling Technology (FDT) visual field reports for a second test subject baseline (left) and post-application (right) conditions. 10 EXAMPLE 7 FIGS. 4A, 4B, 5A and 5B represent patient data from two patients showing other relevant ocular data over a period of time up to about 100 to 200 minutes from 15 administration of 50 mg oral sildenafil citrate (Viagra*). Fig. 4A is a graph of pulsatile ocular blood flow for two test subjects over time. FIG. 4B is a graph of intraocular pressure measured concomitantly with OBF for two test subjects over time. Fig. 5A is a graph of blue field density (perimacular retinal capillary circulatory volume) for two test subjects over time. Fig. 5B is a graph of blue field mean velocity (perimacular retinal 20 capillary circulatory speed) for two test subjects over time. Although the invention has been described with reference to specific embodiments, this description is not meant to be construed in a limited sense. Various modifications of the disclosed embodiments, as well as alternative embodiments of the 25 inventions will become apparent to persons skilled in the art upon the reference to the description of the invention. O T T " 0 T T T T T Cr YL 'T /D TfTT 141 WO 01/10406 PCT/USOO/21929 32 REFERENCES The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein 5 by reference. Pauleikboff D, Chen JC, Chisholm IH, Bird AC. Choroidal blood flow abnormality with age-related Bruch's membrane change. Am J Ophthalmol 1990, 109:211-217. Chen JE, Fitzke FW, Pauliekhoff D, Bird AC. Functional loss in age-related Bruch's 10 membrane change with choroidal blood flow defect. Invest Ophthalmol Vis Sci 1992, 33:334-340. Giovannini A, Mariotti C, Ripa E, Scassellati Sforzolini B, Tittarelli R. Choroidal filling in age-related macular degeneration: indocyanine green angiographic findings. Ophthalmologica 1994, 208:185-191. 15 Grunwald JE, Harisprasad SM, DuPont J, Maguire MG, Fine SL, Brucker AJ, Ho AC. Foveolar choroidal blood flow in age-related macular degeneration. Invest Ophthalmol Vis Sci 1994, 39:385-390. Friedman E, Krupsky S, Lane AM, Oak SS, Friedman ES, Egan K, Gragoudas ES. Ocular blood flow velocity in age-related macular degeneration. Ophthalmology 20 1995, 102:640-646. Ross RD, Barofsky JM, Cohen G, Baber WB, Palao SW, Gitter KA. Presumed macular choroidal watershed vascular filling, choroidal neovascularization and systemic vascular disease in age-related macular degeneration. Am J Ophthalmol 1998, 125:71-80. 25 Ciulla TA, Harris A, Chung HS, Danis RP, Kagemann L, McNulty L, Pratt LM, Martin BJ. Color Doppler imaging discloses reduced ocular blood flow velocities in nonexudative age-related macular degeneration. Am J Ophthalmol 1999; 128:75 80. Dontsov AE, Glickman RD, Ostrovsky MA. Retinal pigment epithelium granules 30 stimulate the photo-oxidation of unsaturated fatty acids. Free Rad Biol Med 1999, 26:1436-1446. P T R P T T TU T F S H E F T (RIE 26) WO 01/10406 PCTUSOO/21929 33 Grunwald JE. Could increased choroidal blood flow stem the development of AMD? In: 15th Biennial Eye Research Seminar (Research to Prevent Blindness, NY, NY/www.RPBUSA.ORG) pp. 23-24. Sponsel WE, Harrison J, Elliot WR, Trigo Y, Kavanagh J. Harris A. Dorzolamide 5 hydrochloride and visual function in normal eyes. Am J Ophthalmol 1997, 123:759-766 Sponsel WE. Topical carbonic anhydrase inhibitors and visual function: Association with retinal circulation and intraocular pressure in normal eyes. Current Concepts on Ocular Blood Flow in Glaucoma (Pillunat IE, Harris A, Anderson DR, Greve 10 EL, eds. Kugler, The Hague, Netherlands) pp. 251-265. Flugel-Koch, Kaufman P, Lutjen-Drecoll E. Association of a choroidal ganglion cell plexus with the fovea centralis. Invest Ophthalmol Vis Sci 1994, 35:4268-4272. Flugel C, Tamm ER, Mayer B, Lutjen-Drecoll E. Species differences in choroidal vasodilative innervation: Evidence for specific intrinsic nitrergic and VIP-positive 15 neurons in the human eye. Invest Ophthamol Vis Sci 1994, 35:592-599. May CH, Hayreh SS, Furuyoshi N, Ossoinig K, Kaufman PL, Lutjen-Drecoll E. Choroidal ganglion cell plexus and retinal vasculature in monkeys with laser induced glaucoma. Ophthalmologica 1997, 211:161-171. Sponsel WE, Paris G, Sandovol SS, Sanford DK, Harrison JM, Elliott WR, Trigo Y. 20 Sildenafil and ocular blood flow. N Engl J Med 2000, 342:1680.14. Vobig MA, Klotz T, Staak M, Bartz-Schmidt KU, Engelmann U, Walter P. Retinal side effects of sildenafil. Lancet 1999, 353:375. Zrenner E. No cause for alarm over retinal side-effects of sildenafil. Lancet 1999, 353:340-1. 25 Vobig MA. Retinal side-effects of sildenafil (letter). Lancet 1999, 353:1442. Marmor MF. Sildenafil (Viagra) and Ophthalmology. Arch Ophthalmol 1999, 117:518 9. Marmor MF, Kessler R. Sildenafil (Viagra) and Ophthalmology. Surv Ophthalmol 1999, 44:153-62. 30 C TT D C 'r T 'T TT T C Y U U I /DTTY T 1 \
Claims (78)
1. A method for treating an optic nerve disease comprising administering to a patient having said optic nerve disease a therapeutically effective amount of a composition 5 comprising at least a first agent that increases ocular blood flow by elevating levels of cyclic-GMP.
2. The method of claim 1, wherein said optic nerve disease is normotensive excavatory optic neuropathy, ischemic optic neuropathy, toxic optic neuropathy, 10 traumatic optic neuropathy, or idiopathic optic neuropathy.
3. The method of claim 1, wherein the optic nerve disease is idiopathic optic neuropathy. 15
4. The method of claim 3, wherein the idiopathic optic neuropathy is optic nerve drusen or benign intracranial hypertension.
5. The method of claim 1, wherein the agent is a cyclic-GMP analog, a cyclic-GMP phosphodiesterase inhibitor, or a guanylate cyclase activator. 20
6. The method of claim 5, wherein the agent is a cyclic-GMP phosphodiesterase inhibitor.
7. The method of claim 6, wherein the agent is sildenafil, dipyridamole, zaprinast, 25 filaminast, denbufyllene, piclamilast, zardaverine, a carboline derivative, a pyridocarbazole derivative, or a quinozolinone compound.
8. The method of claim 5, wherein the agent is a guanylate cyclase activator. 30
9. The method of claim 8, wherein the agent is sodium azide, sodium nitrite, hydroxylamine, hydrazines, nitroglycerine, nitroprusside, nitrosureas or nitrosamines. c T T D r r Tr T Tr U C U TVIV \ / T T U 1,\ WO 01/10406 PCTUSOO/21929 35
10. The method of claim 8, wherein the agent increases ocular nitric oxide levels through nitric oxide donors, stimulation of nitric oxide synthase or increase of the availability or longevity of nitric oxide. 5
11. The method of claim 1, wherein said composition is administered to an eye of said patient.
12. The method of claim 1, wherein said composition is administered orally to said patient. 10
13. The method of claim 11, wherein the composition is applied in the form of an ophthalmic preparation.
14. A method of treating retinal disease comprising administering to a patient a 15 therapeutically effective amount of a composition comprising at least a first agent that increases ocular blood flow by elevating levels of cyclic-GMP.
15. The method of claim 14, wherein said retinal disease is retinal neovascularization, ischemic hematologic/rheologic disorders or toxic maculopathy. 20
16. The method of claim 14, wherein the agent is a cyclic-GMP analog, a cyclic-GMP phosphodiesterase inhibitor, or a guanylate cyclase activator.
17. The method of claim 16, wherein the agent is a cyclic-GMP phosphodiesterase 25 inhibitor.
18. The method of claim 17, wherein the agent is sildenafil, dipyridamole, zaprinast, filaminast, denbufyllene, piclamilast, zardaverine, a carboline derivative, a pyridocarbazole derivative, or a quinolinone compound. 30
19. The method of claim 16, wherein the agent is a guanylate cyclase activator. TRqTTITITTITF S HFFT (RULE26) WO 01/10406 PCT/USOO/21929 36
20. The method of claim 19, wherein the agent is sodium azide, sodium nitrite, hydroxylamine, hydrazines, nitroglycerine, nitroprusside, nitrosureas or nitrosamines.
21. The method of claim 19, wherein the agent increases ocular nitric oxide levels 5 through nitric oxide donors, stimulation of nitric oxide synthase or an increase of availability or longevity of nitric oxide.
22. The method of claim 14, wherein said composition is administered to an eye of said patient. 10
23. The method of claim 14, wherein said composition is administered orally to said patient.
24. The method of claim 22, wherein the agent is applied in the form of an 15 ophthalmic preparation.
25. A method of treating choroidal disease comprising applying a therapeutically effective amount of a composition comprising an agent that increases ocular blood flow by elevating cyclic-GMP levels to an affected eye. 20
26. The method of claim 25, wherein said choroidal disease is an ischemic disorder of the posterior choroid, degenerative subretinal neovascularization, diabetic choroidal ischemia, inflammatory subretinal neovascularization, or non-age related choroidal ischemia. 25
27. The method of claim 26, wherein said choroidal disease is ischemic disorder of the posterior choroid.
28. The method of claim 27 wherein said ischemic disorder of the posterior choroid is 30 degenerative drusen of the macula, macular retinal pigment epithelial atrophy, or retinal pigment epithelial detachment. C Y T " V Tr T T T T'T r TY T T T T1 N I\ WO 01/10406 PCT/USOO/21929 37
29. The method of claim 26, wherein said choroidal disease is degenerative subretinal neovascularization.
30. The method of claim 29, wherein said degenerative subretinal neovascularization 5 is wet age related macular degeneration.
31. The method of claim 25, wherein the agent is a cyclic-GMP analog, a cyclic-GMP phosphodiesterase inhibitor, or a guanylate cyclase activator. 10
32. The method of claim 31, wherein the agent is a cyclic-GMP phosphodiesterase inhibitor.
33. The method of claim 32, wherein the agent is sildenafil, dipyridamole, zaprinast, filaminast, denbufyllene, piclamilast, zardaverine, a carboline derivative, a 15 pyridocarbazole derivative, or a quinozolinone compound.
34. The method of claim 31, wherein the agent is a guanylate cyclase activator.
35. The method of claim 34, wherein the agent is sodium azide, sodium nitrite, 20 hydroxylamine, hydrazines, nitroglycerine, nitroprusside, nitrosureas or nitrosamines.
36. The method of claim 34, wherein the agent increases ocular nitric oxide levels through nitric oxide donors, stimulation of nitric oxide synthase or increase of availability or longevity of nitric oxide. 25
37. The method of claim 25, wherein said composition is administered to an eye of said patient.
38. The method of claim 25, wherein said composition is administered orally to said 30 patient. t YT n C' T Y T TT'T' OTT T T V T I TTTV T' 'b\ WO 01/10406 PCT/USOO/21929 38
39. The method of claim 37, wherein the composition is applied in the form of an ophthalmic preparation.
40. A method for increasing ocular blood flow comprising administering a 5 pharmacologically effective amount of a composition comprising at least a first cyclic GMP phosphodiesterase inhibitor to a patient suffering from a macular disorder.
41. The method of claim 40, wherein said phosphodiesterase inhibitor is selective for phosphodiesterase type 5. 10
42. The method of claim 40, wherein said phosphodiesterase inhibitor is sildenafil citrate, dipyridamole, zaprinast, filaminast, denbufyllene, piclamilast, zardaverine, a carboline derivative, a pyridocarbazole derivative, or a quinozolinone compound. 15
43. The method of claim 40, wherein said administering is by topical application, orally, or perenterally.
44. The method of claim 40, wherein said macular disorder is macular edema, macular degeneration, familial drusen, macular disorders related to hypertension, 20 angioma, papillitis, neuroretinitis or pigmentary retinal degenerative disorders.
45. A method for treating macular edema, comprising administering a therapeutically effective amount of a composition comprising at least a first agent that increases cyclic GMP to a patient suffering from macular edema. 25
46. The method of claim 45, wherein said agent is a phosphodiesterase inhibitor selective for phosphodiesterase type 5.
47. The method of claim 46, wherein said agent is sildenafil citrate, dipyridamole, 30 zaprinast, filaminast, denbufyllene, piclamilast, zardaverine, a carboline derivative, a pyridocarbazole derivative, or a quinozolinone compound. C Y T T 'rT TTT T C T ' I U T /D T TT V 14\ WO 01/10406 PCT/USOO/21929 39
48. The method of claim 45, wherein said macular edema is without vascular leakage.
49. The method of claim 48, wherein said macular edema is retinitis pigmentosa, pigmentary retinal degenerative disorder, early stage macular hole, or choroidal 5 neovascularization.
50. The method of claim 45, wherein said macular edema is with vascular leakage.
51. The method of claim 50, wherein said macular edema is diabetic retinopathy, 10 branch retinal vein occlusion, intermediate uveitis or ideopathic retinal telangiectasis.
52. The method of claim 45, wherein said composition is administered to an eye of said patient. 15
53. The method of claim 45, wherein said composition is administered orally to said patient.
54. The method of claim 52, wherein the composition is applied in the form of an ophthalmic preparation. 20
55. A method for inhibiting or preventing the accumulation of lipofuscin in an eye comprising administering a composition comprising at least a first agent that inhibits phosphodiesterase type 5 to a patient suffering from accumulation of lipofuscin in the eye. 25
56. The method of claim 55, wherein said phosphodiesterase type 5 inhibitor is sildenafil citrate, dipyridamole. zaprinast, filaminast, denbufyllene, piclamilast, zardaverine, a carboline derivative, a pyridocarbazole derivative, or a quinozolinone compound. 30 LI T T n L TV Tr T T T T'r r TT T~ Ir T /T3 ZTT T7 ItL\ WO 01/10406 PCT/USOO/21929 40
57. A method for increasing ocular blood flow comprising administering a composition comprising at least a first agent that activates guanylate cyclase to a patient having an ocular disorder. 5
58. The method of claim 57, wherein the agent is sodium azide, sodium nitrite, hydroxylamine, hydrazines, nitroglycerine, nitroprusside, nitrosureas or nitrosamines.
59. A method for increasing ocular blood flow comprising administering a composition comprising at least a first agent that increases ocular nitric oxide levels to a 10 patient having an ocular disorder.
60. A kit for treatment of ocular disorders comprising: a) a sealed container housing a composition comprising at least a first agent that increases ocular blood flow by elevating levels of cyclic-GMP; and 15 b) instructions for administering said composition to a patient suffering from an ocular disorder such that the patient's ocular blood flow is increased.
61. The kit of claim 60, wherein said composition includes an agent that activates guanylate cyclase. 20
62. The kit of claim 61, wherein said agent is sodium azide, sodium nitrite, hydroxylamine, hydrazines, nitroglycerine, nitroprusside, nitrosureas or nitrosamines.
63. The kit of claim 60, wherein said composition includes an agent that inhibits 25 cyclic-GMP phosphodiesterase.
64. The kit of claim 63, wherein said agent is sildenafil citrate, dipyridamole, zaprinast, filaminast, denbufyllene, piclamilast, zardaverine, a carboline derivative, a pyridocarbazole derivative, or a quinozolinone compound. 30
65. A pharmaceutical composition for increasing ocular blood flow, comprising at least a first compound that increases ocular levels of cyclic-GMP. STR IR TITTITF SHEFT (RULE261 WO 01/10406 PCT/USOO/21929 41
66. The composition of claim 65, wherein said composition comprises a solution, gel, semisolid, suspension, metered dose device, transdermal patch, or film. 5
67. The composition of claim 66, wherein said solution is an ophthalmic preparation.
68. The composition of claim 65, wherein said compound that increases ocular levels of cyclic-GMP is further defined as a cyclic-GMP phosphodiesterase inhibitor, a guanylate cyclase activator, a cyclic-GMP analog or a nitric oxide donor. 10
69. The composition of claim 68, wherein the cyclic-GMP phosphodiesterase inhibitor is sildenafil citrate, dipyridamole, zaprinast, filaminast, denbufyllene, piclamilast, zardaverine, a carboline derivative, a pyridocarbazole derivative or a quinozolinone compound. 15
70. The composition of claim 68, wherein the nitric oxide donor is sodium azide, sodium nitrite, hydroxylamine, a hydrazine, nitroglycerine, nitroprusside, a nitrosurea or a nitrosamine. 20
71. The composition of claim 67, wherein the ophthalmic preparation comprises a pharmaceutically acceptable carrier and sildenafil citrate at a concentration of about .001 % to about 20 % weight per volume.
72. A method for treating optic nerve disease comprising administering to a patient 25 with said optic nerve disease a therapeutically effective amount of sildenafil citrate.
73. A method for treating retinal disease comprising administering to a patient with said retinal disease a therapeutically effective amount of sildenafil citrate. 30
74. A method for treating choroidal disease comprising administering to a patient with said choroidal disease a therapeutically effective amount of sildenafil citrate. L Y T n T T T1r T T T Ir LYT T T T3TTT TV '14. WO 01/10406 PCT/USOO/21929 42
75. A method for increasing visual function comprising administering to a patient a therapeutically effective amount of sildenafil citrate to an affected eye.
76. A method for increasing ocular blood flow comprising administering to a patient 5 in need of increased ocular blood flow a therapeutically effective amount of sildenafil citrate.
77. A method for increasing visual function comprising administering to a patient with normal vision a pharmacologically effective amount of sildenafil citrate. 10
78. An ophthalmic preparation comprising a pharmaceutically acceptable carrier and sildenafil citrate at a concentration of about .001 % to about 20 % weight per volume. V Y T C T r T T rT Tr ' T YY T' T' T /" T TY I I'-\
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14815099P | 1999-08-10 | 1999-08-10 | |
US60/148150 | 1999-08-10 | ||
PCT/US2000/021929 WO2001010406A2 (en) | 1999-08-10 | 2000-08-10 | Facilitating the preservation of sight by increasing optic nerve, choroidal and retinal blood flow |
Publications (2)
Publication Number | Publication Date |
---|---|
AU6536500A true AU6536500A (en) | 2001-03-05 |
AU779991B2 AU779991B2 (en) | 2005-02-24 |
Family
ID=22524518
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU65365/00A Ceased AU779991B2 (en) | 1999-08-10 | 2000-08-10 | Method for increasing optic nerve, choroidal and retinal blood flow to facilitate the preservation of sight |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1246605A2 (en) |
JP (1) | JP2003506394A (en) |
AU (1) | AU779991B2 (en) |
CA (1) | CA2378257A1 (en) |
WO (1) | WO2001010406A2 (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI265925B (en) | 1999-10-11 | 2006-11-11 | Pfizer | Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them |
EP1093814A1 (en) * | 1999-10-22 | 2001-04-25 | Boehringer Ingelheim Pharma KG | Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders |
SE0202365D0 (en) | 2002-08-05 | 2002-08-05 | Pharmacia Ab | New formulation and use thereof |
EP1653978B1 (en) | 2003-07-09 | 2020-06-03 | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Use of nitrite salts for the treatment of cardiovascular conditions |
KR20060109947A (en) * | 2003-11-20 | 2006-10-23 | 오쎄라 파마슈티걸즈, 인크. | Amelioration of macular degeneration and other ophthalmic diseases |
US20090214624A1 (en) * | 2004-11-29 | 2009-08-27 | The University Of Akron | Topical nitric oxide donor devices and methods for their therapeutic use |
US8088773B2 (en) | 2005-05-12 | 2012-01-03 | The Texas A&M University System | Therapeutic compositions and methods |
WO2006125123A2 (en) | 2005-05-19 | 2006-11-23 | University Of Cincinnati | Methods for treating bacterial respiratory tract infections in an individual using acidified nitrite |
JP5162859B2 (en) * | 2005-08-31 | 2013-03-13 | 大正製薬株式会社 | Prevention or alleviation of eye strain |
WO2010147742A2 (en) * | 2009-06-18 | 2010-12-23 | Theravasc Inc. | Use of nitrite salts in treating tissue damage |
JP5791064B2 (en) * | 2009-07-17 | 2015-10-07 | エア・ウォーター株式会社 | Pharmaceutical composition |
AU2013274582A1 (en) | 2012-06-11 | 2015-01-22 | Macuclear, Inc. | Therapeutic formulation and methods of treatment |
FR3008618A1 (en) * | 2013-07-19 | 2015-01-23 | Univ Paris Curie | USE OF COMPOUNDS TO RESTORE THE RESPONSE IN THE LIGHT OF CELLS OF THE RETINA |
CN115282152A (en) * | 2015-01-28 | 2022-11-04 | 瑞采生技有限公司 | Compounds for enhancing PPAR γ expression and nuclear translocation and medical uses thereof |
CN109640973A (en) * | 2016-06-21 | 2019-04-16 | 纽卡斯尔大学 | The treatment of myopia |
EP4154888A1 (en) | 2021-09-24 | 2023-03-29 | Charité - Universitätsmedizin Berlin | Pde5 inhibitor for use in the treatment of medical conditions associated with mitochondrial complex v deficiency |
CN114177182A (en) * | 2021-12-25 | 2022-03-15 | 三维医疗科技有限公司 | Application of sildenafil citrate/tadalafil/vardenafil in preparation of medicine for treating myopia |
EP4233867A1 (en) * | 2022-02-24 | 2023-08-30 | Nicox SA | Pde5 inhibitor for use in the treatment of anterior ischemic optic neuropathy |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0733745A (en) * | 1993-07-19 | 1995-02-03 | Taiho Yakuhin Kogyo Kk | 2-nitroimidazole compounds |
US5780450A (en) * | 1995-11-21 | 1998-07-14 | Alcon Laboratories, Inc. | Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage |
WO1998037894A1 (en) * | 1997-02-28 | 1998-09-03 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Synergistic combination of pde inhibitors and adenylate cyclase agonists or guanyl cyclyse agonists |
-
2000
- 2000-08-10 AU AU65365/00A patent/AU779991B2/en not_active Ceased
- 2000-08-10 CA CA002378257A patent/CA2378257A1/en not_active Abandoned
- 2000-08-10 EP EP00952721A patent/EP1246605A2/en not_active Withdrawn
- 2000-08-10 WO PCT/US2000/021929 patent/WO2001010406A2/en not_active Application Discontinuation
- 2000-08-10 JP JP2001514927A patent/JP2003506394A/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP1246605A2 (en) | 2002-10-09 |
CA2378257A1 (en) | 2001-02-15 |
JP2003506394A (en) | 2003-02-18 |
WO2001010406A3 (en) | 2002-08-08 |
WO2001010406A2 (en) | 2001-02-15 |
AU779991B2 (en) | 2005-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU779991B2 (en) | Method for increasing optic nerve, choroidal and retinal blood flow to facilitate the preservation of sight | |
US6489335B2 (en) | Treatment of ocular disease | |
US7083803B2 (en) | Ocular solutions | |
US20060228394A1 (en) | Ocular solutions | |
US20050250788A1 (en) | Aqueous outflow enhancement with vasodilated aqueous cavity | |
US20060263409A1 (en) | Treatment of ocular disease | |
KR101689847B1 (en) | Eye drop with difluprednate for macular edema treatment | |
US7638516B2 (en) | Agent for therapeutic treatment of optic nerve diseases and the like | |
JP5363123B2 (en) | Retinal nerve or optic nerve protective agent | |
ZA200510344B (en) | Coumarin derivatives for the treatment of ophthalmic disorders | |
US10973758B2 (en) | Methods of eye treatment using therapeutic compositions containing dipyridamole | |
JP2000506833A (en) | Treatment of macula edema | |
CN112135603A (en) | Pharmaceutical composition comprising nebivolol | |
JP2967523B2 (en) | Ophthalmic pharmaceutical composition | |
JP2005521681A (en) | Method for treating ophthalmic diseases using urea and urea derivatives | |
US20030225101A1 (en) | Method of treating retinal occlusion with sildenafil | |
JP2004331502A (en) | Optical nerve cell protecting agent | |
CA2398900A1 (en) | Therapeutic agents for opthalmopathy | |
EP4351540A1 (en) | Trpa1 channel antagonist compound for use in degenerative retinal diseases | |
Fallor et al. | Ocular toxicity of experimental intravitreal vitamin E | |
Kwon et al. | Evaluation on Clinical Application of Osmotic Pump with Dorzolamide in Normal Dogs | |
JP4393863B2 (en) | Optic nerve cell protective agent | |
CN116509993A (en) | Medicine for preventing and treating retinopathy and preparation method thereof | |
Campell et al. | Majima, A. Eye-abnormalities in mice embryos caused by X-radiation of moth-ers. Acta Sot. Ophthal. Japan 65: 2091-2100, Sept., 1961. When gravid mice, on the 8th day of |